main-logo

ICD-10 Code C83.79 | Burkitt lymphoma, extranodal and solid organ sites Symptoms, Diagnosis, Billing

Burkitt lymphoma, extranodal and solid organ sites is a highly aggressive form of non-Hodgkin lymphoma characterized by rapid tumor growth. It primarily affects children and young adults and can manifest in various extranodal sites, including the gastrointestinal tract, jaw, and central nervous system. Accurate coding with ICD-10 Code C83.79 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that healthcare providers can effectively manage and treat this serious condition.

What is ICD-10 Code C83.79 for Burkitt lymphoma, extranodal and solid organ sites?

ICD-10 Code C83.79 represents Burkitt lymphoma occurring in extranodal and solid organ sites. This aggressive lymphoma is associated with the MYC gene rearrangement and can lead to significant morbidity if not diagnosed and treated promptly. This code should be used in clinical documentation and billing when the lymphoma is identified in locations outside of lymph nodes, ensuring accurate representation of the patient's condition for treatment and reimbursement purposes.

ICD-10 Code C83.79 – Clinical Definition and Explanation of Burkitt lymphoma, extranodal and solid organ sites

Burkitt lymphoma, extranodal and solid organ sites, is a highly aggressive B-cell neoplasm that requires immediate medical intervention. It is often associated with immunocompromised states and can progress rapidly, leading to severe complications. Early diagnosis and treatment are critical to improving patient outcomes.

Key Clinical Features:

  • Rapidly enlarging tumors in extranodal sites such as the abdomen or jaw.
  • Commonly presents with abdominal pain, swelling, or gastrointestinal obstruction.
  • Associated with immunodeficiency, particularly in HIV-positive patients.
  • High proliferation index, often leading to a high tumor burden at diagnosis.

ICD-10 Code C83.79 for Burkitt lymphoma, extranodal and solid organ sites – SOAP Notes & Clinical Use

ICD-10 Code C83.79 is utilized in SOAP notes to document the presence of Burkitt lymphoma in extranodal and solid organ sites. This code aids in capturing the patient's symptoms, assessment findings, and treatment plans, ensuring comprehensive documentation in both acute and chronic care settings.

What Does ICD-10 Code C83.79 for Burkitt lymphoma, extranodal and solid organ sites Mean in SOAP Notes?

In SOAP notes, ICD-10 Code C83.79 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of Burkitt lymphoma. This code is crucial for ensuring continuity of care, supporting accurate billing, and meeting EHR documentation standards.

Treatment Options for ICD-10 Code C83.79 – Burkitt lymphoma, extranodal and solid organ sites

Burkitt lymphoma, extranodal and solid organ sites, necessitates urgent treatment due to its aggressive nature. Hospitalization is often required for intensive therapy.

Antibiotic Therapy:

  • Not applicable as Burkitt lymphoma is not an infectious disease; however, prophylactic antibiotics may be used during chemotherapy.
  • Consideration for antibiotic therapy if there is a risk of infection due to immunosuppression.

Supportive Care:

  • Management of tumor lysis syndrome with hydration and electrolyte monitoring.
  • Pain management and nutritional support as needed.
  • Psychosocial support for patients and families.

Infection Control:

  • Strict hand hygiene and isolation precautions for immunocompromised patients.
  • Monitoring for signs of infection during treatment.

How to Document Symptoms of Burkitt lymphoma, extranodal and solid organ sites (ICD-10 C83.79) in SOAP Notes

Subjective:

  • Patient reports abdominal pain and swelling.
  • History of rapid weight loss over the past month.
  • Complaints of night sweats and fever.
  • Patient expresses concern about facial swelling.

Objective:

  • Abdominal examination reveals a palpable mass.
  • Vital signs show fever of 101°F.
  • CBC shows elevated white blood cell count.
  • Imaging reveals a large abdominal mass consistent with lymphoma.
card-topcard-bottom

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more
hipaa-icon

SOAP Note Guidelines for Diagnosing Burkitt lymphoma, extranodal and solid organ sites (ICD-10 Code C83.79)

Assessment:

  • Diagnosis: Burkitt lymphoma, extranodal and solid organ sites, high grade.
  • ICD-10 Code: C83.79.
  • Contributing factors: Immunocompromised status due to underlying condition.
  • Severity: Aggressive with rapid progression.

Plan:

  • Initiate chemotherapy regimen (e.g., cyclophosphamide, doxorubicin, vincristine, prednisone).
  • Educate patient on potential side effects and the importance of follow-up.
  • Monitor for tumor lysis syndrome and manage electrolytes.
  • Schedule follow-up appointment in one month for reassessment.

Treatment & Plan Section for ICD-10 Code C83.79 – Burkitt lymphoma, extranodal and solid organ sites

  • First-line pharmacologic treatment includes combination chemotherapy regimens.
  • Non-pharmacologic strategies involve nutritional support and psychosocial counseling.
  • Monitoring includes regular CBC checks and imaging studies to assess treatment response.
  • Follow-up practices should include scheduled visits for ongoing assessment and management.

Using ICD-10 Code C83.79 for Burkitt lymphoma, extranodal and solid organ sites in Billing & SOAP Note Compliance

  • Select accurate subcodes based on clinical severity or complications.
  • Document symptoms clearly under Subjective (S) and Objective (O) in SOAP notes.
  • Ensure treatment plans align with clinical guidelines to support justified billing.
  • Commonly billed CPT codes include those for chemotherapy administration and imaging studies.

ICD-10 Code C83.79 in Medical Billing and Insurance for Burkitt lymphoma, extranodal and solid organ sites

ICD-10 Code C83.79 is critical in medical billing, particularly in hospital, ER, or infectious disease care settings.

Billing Notes:

  • Ensure documentation includes detailed clinical findings and treatment plans to support the ICD-10 claim.
  • Use this code in conjunction with appropriate CPT codes for chemotherapy and imaging.
  • Document any complications or comorbidities that may affect treatment and billing.
  • Verify that all coding aligns with payer requirements for reimbursement.

Common CPT Pairings:

CPT CodeDescription
96413Chemotherapy administration, intravenous, push technique.
96365Intravenous infusion, for therapy, prophylaxis, or diagnosis.
77021Magnetic resonance imaging (MRI) of the abdomen.
85025Complete blood count (CBC) with differential.

Frequently Asked Questions

Common Questions About Using ICD-10 Code C83.79 for Burkitt lymphoma, extranodal and solid organ sites

What are the common symptoms of Burkitt lymphoma?

Common symptoms include rapidly growing tumors, abdominal pain, swelling, fever, and night sweats. Patients may also experience weight loss and fatigue due to the aggressive nature of the disease.

How is Burkitt lymphoma diagnosed?

Diagnosis typically involves imaging studies, biopsy of the tumor, and laboratory tests to assess the presence of MYC gene rearrangements. A thorough clinical evaluation is essential for accurate diagnosis.

What is the treatment for Burkitt lymphoma?

Treatment usually involves intensive chemotherapy regimens. In some cases, radiation therapy may be indicated. Early intervention is crucial due to the aggressive nature of the disease.

Is Burkitt lymphoma contagious?

No, Burkitt lymphoma is not contagious. It is a type of cancer that arises from genetic mutations in B-cells and is not transmitted from person to person.

diamond-bg
diamond-bg

Get started with your 20 free notes

Sign up for free
main-logo

AI-aided Sudsy Shorthand for ink-free practices

support@soapsuds.io
hipaa-logo

Clinical Notes

SOAP notes

DAP notes

AI medical notes

© Copyright SOAPsuds 2025. All rights reserved